Sahil Seth
Overview
Explore the profile of Sahil Seth including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
6696
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Laurent C, Trisal P, Tesson B, Seth S, Beyou A, Roulland S, et al.
Blood
. 2024 Oct;
144(24):2503-2516.
PMID: 39374535
A robust prognostic and biological classification for newly diagnosed follicular lymphoma (FL) using molecular profiling remains challenging. FL tumors from patients treated in the RELEVANCE trial with rituximab-chemotherapy (R-chemo) or...
2.
Seth S, Chen R, Liu Y, Fujimoto J, Hong L, Reuben A, et al.
Cancer Innov
. 2024 Jul;
3(3):e112.
PMID: 38947760
Background: Pulmonary sarcomatoid carcinoma (PSC) is a rare and aggressive subtype of non-small cell lung cancer (NSCLC), characterized by the presence of epithelial and sarcoma-like components. The molecular and immune...
3.
Lim B, Seth S, Yam C, Huo L, Fujii T, Lee J, et al.
Cell Rep Med
. 2024 Jun;
5(6):101595.
PMID: 38838676
Luminal androgen receptor (LAR)-enriched triple-negative breast cancer (TNBC) is a distinct subtype. The efficacy of AR inhibitors and the relevant biomarkers in neoadjuvant therapy (NAT) are yet to be determined....
4.
Basho R, Zhao L, White J, Huo L, Bassett R, Mittendorf E, et al.
JCO Precis Oncol
. 2024 Mar;
8:e2300124.
PMID: 38484209
Purpose: The PI3K pathway is frequently altered in triple-negative breast cancer (TNBC). Limited cell line and human data suggest that TNBC tumors characterized as mesenchymal (M) and luminal androgen receptor...
5.
Chen H, Ding Q, Khazai L, Zhao L, Damodaran S, Litton J, et al.
Ther Adv Med Oncol
. 2023 Aug;
15:17588359231189422.
PMID: 37547448
Background: Recent advances have been made in targeting the phosphoinositide 3-kinase pathway in breast cancer. Phosphatase and tensin homolog (PTEN) is a key component of that pathway. Objective: To understand...
6.
Abuhadra N, Sun R, Litton J, Rauch G, Yam C, Chang J, et al.
Cancers (Basel)
. 2022 Mar;
14(5).
PMID: 35267631
High stromal tumor-infiltrating lymphocytes (sTILs) are associated with an improved pathologic complete response (pCR) and survival in triple-negative breast cancer (TNBC). We hypothesized that high baseline sTILs would have a...
7.
Li J, Lu H, Ng P, Pantazi A, Ip C, Jeong K, et al.
Sci Adv
. 2022 Feb;
8(6):eabm2382.
PMID: 35138907
Fusion genes represent a class of attractive therapeutic targets. Thousands of fusion genes have been identified in patients with cancer, but the functional consequences and therapeutic implications of most of...
8.
Kumar M, Molkentine D, Molkentine J, Bridges K, Xie T, Yang L, et al.
Nat Commun
. 2021 Nov;
12(1):6340.
PMID: 34732714
Despite radiation forming the curative backbone of over 50% of malignancies, there are no genomically-driven radiosensitizers for clinical use. Herein we perform in vivo shRNA screening to identify targets generally...
9.
Yam C, Yen E, Chang J, Bassett R, Alatrash G, Garber H, et al.
Clin Cancer Res
. 2021 Jul;
27(19):5365-5375.
PMID: 34253579
Purpose: Increasing tumor-infiltrating lymphocytes (TIL) is associated with higher rates of pathologic complete response (pCR) to neoadjuvant therapy (NAT) in patients with triple-negative breast cancer (TNBC). However, the presence of...
10.
Puca F, Yu F, Bartolacci C, Pettazzoni P, Carugo A, Huang-Hobbs E, et al.
Cancer Discov
. 2021 May;
11(11):2904-2923.
PMID: 34039636
Glioblastoma (GBM) is highly resistant to chemotherapies, immune-based therapies, and targeted inhibitors. To identify novel drug targets, we screened orthotopically implanted, patient-derived glioblastoma sphere-forming cells using an RNAi library to...